Navigating pharmaceutical environmental monitoring in a changing industry
Supported by:
27 February 2025
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
During this virtual panel, industry experts will explore the latest advances in environmental monitoring, discuss key challenges within the sector and approaches that can prevent and mitigate these issues.
Pharmaceutical environmental monitoring ensures the safety and quality of drug products and medicines by taking a proactive approach to quality control. It is imperative that pharmaceutical professionals are up to date with key aspects that impact the sector such as regulation and legislation (eg, Annex 1) and new technologies, to deliver effective monitoring of cleanrooms, aseptic manufacturing suites and more.
Having the latest knowledge of essential elements such as a robust and holistic contamination control strategy (CCS), and regulatory considerations like good manufacturing practise (GMP), can help those working in the environmental monitoring to address challenges appropriately.
Furthermore, individuals in the sector should be equipped with the most up-to-date and adequate training, skills and knowledge so they can conduct activity in key areas such as water and air monitoring, sterile gown monitoring and validation, for instance, environmental monitoring performance qualification (EMPQ).
In this session, speakers will also share their expertise and insight on best practise and emerging trends to help pharmaceutical professionals navigate changes in the industry.
Key learning points:
- Find out about the latest advancements and developments and major challenges impacting the pharmaceutical environmental monitoring sector in 2025.
- Learn about how to enable regulatory compliance, ensure quality control, ways to handle risk management, and more. Attendees have an exclusive opportunity to ask questions on key topics from leaders in the sector.
- Hear from industry experts on best practice in key areas such as regulation, manufacturing.
OUR SPEAKER
Joel Russo – Pharmaceutical Microbiologist, Manufacturing & Lab Compliance Senior Consultant, Russo Consulting Group, LLC
Joel has 30 years of Microbiology experience including nearly 25 years of experience in pharmaceutical and other areas of GMP Manufacturing Quality, Compliance, and GLP Quality Laboratory Processes and Systems, specialised in Microbiological Control, Aseptic Processing, FDA Remediation, Quality Systems remediation in response to regulatory actions, 483’s Warning Letters, Consent Decrees, other regulatory reporting. Leading, mentoring and supporting investigation / CAPA committees and workgroups. Support of multiple PAI and FDA Product Approval efforts. Joel is currently the President of Russo Consulting Group which specialises in microbiological contamination control, laboratory and lab system architecture, lab compliance, manufacturing compliance, and validation efforts.
FAQs
FAQs
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
27 February at 3pm GMT.
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
